TOward a Better Understanding of the autoPhagy Machinery for the Identification of Potential Novel Biomarkers and Therapeutic Targets in Crohn's Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

170 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-06-01

Study Completion Date

2026-01-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Crohn's disease (CD) belongs to chronic inflammatory bowel diseases (IBD) affecting over 2 million individuals in the North America and 3.2 million in Europe with an increasing incidence rate in newly industrialized countries experiencing a westernization of lifestyle (1). This highly disabling disease affects patients' life in several ways with severe complications requiring surgery for half of them and is responsible for considerable economic burdens (2,3). Decades of research displayed that CD pathogenesis is determined by inappropriate immune responses towards luminal microbiota in genetically susceptible hosts. Genome-wide association studies (GWAS) have identified autophagy as one of the main pathways associated with susceptibility to CD (4-6). Autophagy is a dynamic process of the lysosomal catabolism, called autophagy flux, which is crucial to degrade and recycle obsolete and deleterious cytosolic components of the cell (7). Autophagy is also the main cell-autonomous process to fight intracellular microorganisms by degrading them, and by contributing to antimicrobial host immune responses. However, the functional consequences of polymorphisms affecting autophagy-associated genes on the dynamic process of autophagy and its real impact on CD pathogenesis remain largely unknown. In addition, CD is associated with a gut microbiota dysbiosis, as exemplified by the higher prevalence of AIEC (a bacterium eliminated by autophagy) in ileal mucosa of CD patients (8-10). Hence, autophagy defect, linked to autophagy SNPs, could contribute to CD-related dysbiosis and to CD activity and severity.

Beyond, CD-associated abnormalities of the autophagy flux may affect the composition of the autophagic cargoes, as well as the one of other vesicular pathway, such as exosomes, known to influence autophagy. These impairments could affect at longer term both cell activities and immune responses, especially in antigen presenting cells, which drive host immune responses.

The TOPIC project concerns translational research, in which we plan to generate a prospective cohort of CD patients giving up the unique opportunity to collect clinical data, to analyse simultaneously the autophagy flux, genetic variants of interest (from blood samples) and intestinal microbiota (from intestinal samples) and allowing to perform more fundamental studies. The results of the fundamental part will allow a better understanding of the pathophysiology of CD, and ultimately better management of these patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study to Characterize Multidimensional Model to Predict the Course of Crohn's Disease (CD)

NCT03668249

Inflammatory Bowel Diseases Crohn Disease

COMPLETED

Postoperative REcurrence and DynamICs of T Cell Subsets in Crohn's Disease

NCT02770495

Crohn Disease

COMPLETED PHASE3

Evaluation of Molecular Mechanisms of Non-response to Therapy in Patients With Inflammatory Bowel Disease

NCT05733845

Crohn's Disease Ulcerative Colitis

RECRUITING NA

Autophagy in Paediatric Crohn's Disease

NCT05842564

Crohn Disease Pediatric Crohns Disease

NOT_YET_RECRUITING NA

Evaluation of Immunological Markers, Inflammatory and Clinical Relapse Psychological Predictive During Crohn's Disease

NCT02504255

Crohn Disease

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Crohn's Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

A case-control study from a prospective bicentric cohort of CD patients. Proof of concept and exploratory study with minimum risks (type 2)

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patient with Crohn disease (n=150)

CD patients requiring to undergo an ileo-colonoscopy for routine investigations (assessment of disease activity or complications as stricture or screening of colorectal cancer for CD)

Group Type OTHER

Blood samples

Intervention Type BIOLOGICAL

A 28 mL (5 EDTA tubes of 4 mL and 2 dry tubes) venous blood will be collected added to the standard blood analysis performed in routine

Stool simple

Intervention Type BIOLOGICAL

A fresh stool sample will be collected and conserved at room temperature until shipment

Ileocolonic biopsies

Intervention Type BIOLOGICAL

An ileo-colonoscopy with 10 ileal biopsies scheduled in their regular medical follow-up will be performed

Patient without Crohn disease (n=20)

Non-IBD patients (control) requiring to undergo an ileo-colonoscopy for routine investigations (screening for colorectal cancer or diagnosis of irritable bowel syndrome for controls).

Group Type OTHER

Blood samples

Intervention Type BIOLOGICAL

A 28 mL (5 EDTA tubes of 4 mL and 2 dry tubes) venous blood will be collected added to the standard blood analysis performed in routine

Stool simple

Intervention Type BIOLOGICAL

A fresh stool sample will be collected and conserved at room temperature until shipment

Ileocolonic biopsies

Intervention Type BIOLOGICAL

An ileo-colonoscopy with 10 ileal biopsies scheduled in their regular medical follow-up will be performed

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Blood samples

A 28 mL (5 EDTA tubes of 4 mL and 2 dry tubes) venous blood will be collected added to the standard blood analysis performed in routine

Intervention Type BIOLOGICAL

Stool simple

A fresh stool sample will be collected and conserved at room temperature until shipment

Intervention Type BIOLOGICAL

Ileocolonic biopsies

An ileo-colonoscopy with 10 ileal biopsies scheduled in their regular medical follow-up will be performed

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

For CD patients :

* Aged over 18 years
* Men or non-pregnant women
* Patients with a diagnosis of terminal ileum or ileocolonic CD for at least three months who requires to perform an ileocolonoscopy for routine follow-up
* Inactive and moderately to severely active CD according to the Harvey-Bradshaw index
* Stable doses of oral prednisone (≤30 mg per day) or budesonide (≤9 mg per day), mesalamine, concomitant immunosuppressive agents, biologics including anti-TNF agents, vedolizumab or ustekinumab are allowed at stable dose for at least three months before inclusion.
* Informed written consent
* Beneficiary or beneficiary of a social security system

For non IBD controls :

* Aged over 18 years
* Men or non-pregnant women
* Patients without a diagnosis of Crohn's disease who requires to perform an ileocolonoscopy for routine follow-up
* Informed written consent
* Beneficiary or beneficiary of a social security system

Exclusion Criteria

For patients and non-IBD controls :

* Existing pregnancy, lactation, or intended pregnancy within the next 15 months
* History of disease, including mental/emotional disorder that might interfere with their participation in the study
* Serious secondary illnesses of an acute or chronic nature, which in the opinion of the investigator renders the patient unsuitable for inclusion into the study
* Inability to comply with the protocol requirements
* Presence of an ileo-/colonic stoma
* Patients with known colonic stricture and exclusive or predominant anal or perineal Crohn's disease lesions
* Known previous or concurrent malignancy (other than that considered surgically cured, with no evidence for recurrence for 5 years)
* Short bowel syndrome
* Concomitant Clostridium difficile superinfection
* Indeterminate colitis
* Concomitant leukocyte apheresis
* Patients who will be exposed to antibiotics 4 weeks prior the inclusion, given the potential impact on the detection of AIEC colonization in ileal biopsies
* Patients who denied the protocol, not ability to accept or sign consent of the protocol
* Subject involved in another interventional research with an exclusion period still in progress at inclusion
* Pregnant women, women in labor or breastfeeding women\*.
* Persons deprived of their liberty by a judicial or administrative decision
* Persons under psychiatric care
* Persons admitted to a health or social institution for purposes other than research
* Adults subject to a legal protection measure (guardianship, curatorship)
* Subject involved in another clinical trial

Minimum Eligible Age

18 Years

Maximum Eligible Age

99 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No